

# Exhibit 10

1 IN THE UNITED STATES DISTRICT COURT  
2 FOR THE NORTHERN DISTRICT OF  
3 WEST VIRGINIA

4 Civil Action No. 1:22-cv-00061-TSK

5 -----x

6 REGENERON PHARMACEUTICALS, INC.,

7 Plaintiff,

8 -against-

9 MYLAN PHARMACEUTICALS INC.,

10 Defendant.

11 -----x

12 650 Fifth Avenue

New York, New York

13 December 16, 2022

14 9:12 a.m.

15  
16 VIDEOTAPED HYBRID DEPOSITION of  
17 KAREN CHU, a witness in the  
18 above-entitled action, held at the above  
19 time and place, taken before Dawn Matera,  
20 a Shorthand Reporter and Notary Public of  
21 the State of New York.

22 \* \* \*

<p style="text-align: right;">Page 2</p> <p>1 A P P E A R A N C E S : (Continued)</p> <p>2</p> <p>3 WILLIAMS &amp; CONNOLLY LLP</p> <p>4 Attorneys for Regeneron Pharmaceuticals,</p> <p>5 Inc.</p> <p>6 680 Maine Ave S.W.</p> <p>7 Washington, D.C. 20024</p> <p>8 By: ELLEN E. OBERWETTER, ESQ.</p> <p>9 eoberwetter@wc.com</p> <p>10 KATHRYN S. KAYALI, ESQ.</p> <p>11 kkayali@wc.com</p> <p>12</p> <p>13 RAKOCZY MOLINO MAZZOCHI SIWIK LLP</p> <p>14 Attorneys for Mylan Pharmaceuticals</p> <p>15 6 W. Hubbard Street</p> <p>16 Suite 500</p> <p>17 Chicago, Illinois 60654</p> <p>18 By: DEANNE M. MAZZOCHI, ESQ.</p> <p>19 dmazzochoi@rmmslegal.com</p> <p>20 (Remote Attendance)</p> <p>21 JEFFREY A. MARX, ESQ.</p> <p>22 jmarx@rmmslegal.com</p> <p>23 HEINZ J. SALMEN, ESQ.</p> <p>24 hsalmen@rmmslegal.com</p> <p>25 (Remote Attendance)</p> <p>CAREY DOUGLAS KESSLER &amp; RUBY PLLC</p> <p>Local Counsel for Regeneron</p> <p>Pharmaceuticals, Inc.</p> <p>707 Virginia Street East</p> <p>901 Chase Tower</p> <p>Charleston, West Virginia 25301</p> <p>By: DAVID POGUE, ESQ.</p> <p>drpogue@cdkrlaw.com</p> <p>(Remote Attendance.)</p>	<p style="text-align: right;">Page 4</p> <p>1 THE VIDEOGRAPHER: Good morning.</p> <p>2 We are going on the record at</p> <p>3 a.m. Eastern Standard Time. Please</p> <p>4 note that the microphones are</p> <p>5 sensitive and may pick up whispering</p> <p>6 and private conversations. Please</p> <p>7 mute your phones at this time. Audio</p> <p>8 and video recording will continue to</p> <p>9 take place unless all parties agree to</p> <p>10 go off the record.</p> <p>11 This is media unit 1 of the</p> <p>12 video-recorded deposition of Karen Chu</p> <p>13 taken by counsel in the matter of</p> <p>14 Regeneron Pharmaceuticals, Inc. versus</p> <p>15 Mylan Pharmaceuticals, Inc., filed in</p> <p>16 the United States District Court for</p> <p>17 the Northern District of West</p> <p>18 Virginia, civil action number</p> <p>19 1:22-CV-00061-TSK.</p> <p>20 The location of this deposition</p> <p>21 is in the offices of Williams &amp;</p> <p>22 Connolly, 650 Fifth Avenue, New York,</p> <p>23 New York. My name is Zef Cota and I</p> <p>24 am the videographer. The court</p> <p>25 reporter is Dawn Matera, from the firm</p>
<p style="text-align: right;">Page 3</p> <p>1 A P P E A R A N C E S : (Continued)</p> <p>2</p> <p>3 STEPTOE &amp; JOHNSON PLLC</p> <p>4 Local Counsel for Mylan</p> <p>5 707 Virginia Street East</p> <p>6 Chase Tower, 17th Floor</p> <p>7 Charleston, West Virginia 25301</p> <p>8 By: JOHN PIZZO, ESQ.</p> <p>9 john.pizzo@steptoe-johnson.com</p> <p>10 (Remote Attendance)</p> <p>11</p> <p>12 Also Present:</p> <p>13 ADAM BERNSTEIN, Regeneron</p> <p>14 PETRA SCAMBOROVA, Regeneron</p> <p>15 ZEF COTA, Videographer</p> <p>16 ~oOo~</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p style="text-align: right;">Page 5</p> <p>1 of Veritext.</p> <p>2 I am not authorized to</p> <p>3 administer an oath. I am not related</p> <p>4 to any party in this action nor am I</p> <p>5 financially interested in the outcome.</p> <p>6 Counsel and all present in the</p> <p>7 room have been noted for the</p> <p>8 stenographic record.</p> <p>9 Will the court reporter please</p> <p>10 swear in the witness and then counsel</p> <p>11 may proceed.</p> <p>12 K A R E N C H U, the Witness herein,</p> <p>13 having first been duly sworn by the</p> <p>14 Notary Public, was examined and testified</p> <p>15 as follows:</p> <p>16 EXAMINATION BY MS. MAZZOCHI:</p> <p>17 Q. Thank you. Good morning,</p> <p>18 Ms. Chu, my name is Deanne Mazzochoi.</p> <p>19 Can you please state your full</p> <p>20 name and address for the record.</p> <p>21 A. Yes, Karen Chu, and my home</p> <p>22 address is 73 Richbell Road, White</p> <p>23 Plains, New York 10605.</p> <p>24 Q. Is this your first time given</p> <p>25 testimony under oath?</p>

<p style="text-align: right;">Page 6</p> <p>1 A. I previously gave testimony 2 under oath in a different case many, many 3 years ago. 4 Q. Okay. Do you recall -- did 5 that case involve Regeneron? 6 A. It did not. 7 Q. Did it involve any VEGF 8 inhibitors? 9 A. It did not. It involved a 10 personal liability suit against the 11 summer camp I went to. 12 Q. Have you participated at all in 13 any FTC proceedings prior to being 14 deposed in this case? 15 A. No, I have not. 16 Q. Have you been asked to provide 17 documents or records in connection with 18 any matter involving the United States 19 government and Regeneron? 20 A. I have not. 21 Q. How about any claims involving 22 a state government? 23 A. No, not that I am aware. 24 Q. How about any litigation 25 involving Regeneron and an insurer or an</p>	<p style="text-align: right;">Page 8</p> <p>1 company here on the East Coast, Purdue 2 Pharma. And then worked for them for 3 approximately a little over two years 4 before moving to a small contract 5 research organization called Barton &amp; 6 Polansky, located here in New York City. 7 After that, I joined a company 8 that was headquartered in Gaithersburg, 9 Maryland called GenVec. They were a gene 10 therapy company. And after I left -- I 11 was with GenVec for four years before 12 joining Regeneron. 13 Q. How did you get involved in or 14 what training did you receive in 15 connection with clinical -- human 16 clinical trials? 17 MS. OBERWETTER: Object to the 18 form. 19 You can answer it. 20 A. Okay. Just a clarification, 21 are you asking about training I received 22 throughout my career or specific to 23 Regeneron? 24 Q. Right, throughout your career, 25 because with an MS in nutrition, jumping</p>
<p style="text-align: right;">Page 7</p> <p>1 HMO? 2 A. Not that I am aware of. 3 Q. Have you received any subpoenas 4 to appear before a state or federal grand 5 jury? 6 A. I have not received any 7 subpoenas. 8 Q. Can you please state for the 9 record your educational background post 10 high school? 11 A. Sure. I have a bachelor's of 12 science degree in biology from Cal Poly 13 San Luis Obispo and a master's in human 14 nutrition from Columbia University. 15 Q. And can you please describe 16 your employment history after you 17 graduated from Columbia University with 18 you are your MS in human nutrition? 19 A. Sure. After graduation and 20 completion of my degree, I joined a small 21 biotech company located in the San 22 Francisco Bay area called Seqirus 23 Pharmaceuticals. 24 After working at that company 25 for a little over a year, I moved to a</p>	<p style="text-align: right;">Page 9</p> <p>1 into quality assurance roles and clinical 2 research roles such as at GenVec, you 3 know, how did you -- what type of 4 training did you get in order to -- 5 either in connection with those roles? 6 A. Sure. So the very first 7 position I had in clinical research was 8 as a clinical trial assistant. And as 9 part of my role I helped with the 10 operations of clinical trials and 11 received good clinical practice training 12 as part of my role. 13 So GCP training was provided 14 both by in-house individuals as well as 15 I've attended external courses on both 16 good clinical practice, as well as 17 international conference on harmonization 18 practices. 19 Q. Do you have any certifications 20 in connection with either clinical 21 practice work or the international 22 harmonization standards? 23 A. I do not hold any current 24 certifications. 25 Q. Have you previously?</p>

<p style="text-align: right;">Page 10</p> <p>1 A. Previously I did have a 2 certified contract research associate 3 certification. 4 Q. And how did you get that? 5 A. That required a certain number 6 of hours as well as taking an exam 7 through the Association of Clinical 8 Research Professionals. 9 Q. Is there a reason why you 10 allowed your certification on that to 11 lapse? 12 A. So in my over 25 years of 13 experience in clinical development, it 14 was not critical to the role I have now 15 and felt that it was not necessary to 16 keep that certification. 17 Q. All right. Tell me how you 18 came to be employed at Regeneron? 19 A. So the company I worked for 20 just prior to Regeneron, GenVec, was a 21 small biotechnology firm, and they were 22 having some, as many biotechnology 23 companies do, some troubles with funding 24 as well as some hiccups in terms of being 25 able to move products forward in their</p>	<p style="text-align: right;">Page 12</p> <p>1 for a lot of small companies, in that 2 role wore several different hats and had 3 a broad range of responsibilities as it 4 related to clinical development. And 5 over the years moved into more of a 6 clinical project management role and then 7 finally into my current role. 8 Q. Okay. And was your initial 9 title, what was it, director of 10 therapeutic area, project management? 11 A. So that was not my first title 12 at Regeneron. 13 Q. Okay. What was your first 14 title? 15 A. My recollection is that my 16 first title was senior clinical trial 17 manager. But the director of therapeutic 18 area project management was a promotion 19 into a broader clinical project 20 management role. 21 Q. And then did you ever have any 22 individuals who reported to you in those 23 roles? 24 A. At the time that I was a 25 clinical trial manager I had a group of</p>
<p style="text-align: right;">Page 11</p> <p>1 pipeline. And at the time I was working 2 both on a product they had in development 3 for oncology as well as ophthalmology. 4 And when the company conducted a round of 5 layoffs I personally was not laid off, 6 but it certainly signaled some 7 uncertainty in the company's future. I 8 made a decision to start looking 9 potentially for another position. 10 At the time I was already 11 living in the New York area and Regeneron 12 was very much in the news because of 13 their -- because of the VEGF-Trap 14 molecule and their work in oncology. And 15 so I networked with a friend of mine and 16 contacted a few people in the company to 17 see if they had a need for somebody with 18 my background. Dr. Jesse Cedarbaum was 19 the person who hired me first at 20 Regeneron. 21 Q. And then what was your initial 22 role and responsibilities at Regeneron? 23 A. So when I joined the company I 24 joined as a senior clinical trial 25 manager. And then as is true, I think,</p>	<p style="text-align: right;">Page 13</p> <p>1 people that reported to me who, who were 2 more junior clinical trial managers and 3 involved in the operations of the 4 clinical trials. 5 Q. Okay. How do you differentiate 6 what your role was versus what you call 7 the operations of the clinical trials? 8 A. So within clinical research, 9 there are several people who contribute 10 to any aspect of conducting a clinical 11 trial. So the actual operations of the 12 clinical trial, which includes everything 13 from ensuring that clinical study sites 14 are identified and trained appropriately 15 to providing supplies for the clinical 16 study sites, to deciding which 17 laboratories to use or how labs will be 18 collected. That typically is considered 19 part of the operations role. So they're 20 really, that, you know, they really 21 oversee the actual execution of the 22 clinical trials. 23 Q. Okay. And then who -- when you 24 were at Regeneron, say, in the -- when 25 you first joined Regeneron, who was</p>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.